{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:49:39Z","timestamp":1773874179748,"version":"3.50.1"},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2021,5,7]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>In individuals with ovarian cancer, an increase in the circulating level of the epidermal growth factor (EGF) is readily apparent. Ovarian cancer cells exhibit signaling pathway of the epidermal growth factor (EGFR) and respond to the EGF. Annona muricata (AM) has been shown to decrease ovarian cell proliferation however, role of AM in regulating EGF actions is not yet to be reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>In this study, we proposed that the fractionated compound acetogenin can inhibit the activation of EGFR-regulated signaling cascades such as MAPK7 \/ PI3K-Akt \/ mTOR \/ STAT upon EGF stimulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Ethanolic extract was prepared for the whole AM plant and Thin Layer Chromatography (TLC) was performed to characterize the secondary metabolites and each fraction was assessed using kedde reagent for the presence of acetogenin. The effects of acetogenins were then tested on the survival of PA-1 ovarian cancer cells under basal and EGF stimulated conditions. To delineate the role of acetogenin in EGFR signaling cascades, the in silico docking studies were conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The fraction of acetogenin decreased the viability of EGF induced PA-1 ovarian cancer cells that indicating the EGF inhibitory effects of acetogenin. The docking studies specifically illustrated that when the acetogenin binding with tyrosine kinase (TK) and regulatory unit (RU) which subsequently resulted in a reduction in EGF induced the survival of PA-1 ovarian cancer cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion:<\/jats:title><jats:p>The vital regulatory role of acetogenin reported in this study indicate significant anticancer activities of acetogenin from AM. The in silico study of the acetogenin function predicted that it binds specifically to Asp837 (phosphor-acceptor site) of EGFR, essential for phosphorylation of substrates in the TK domain and RU which promote downstream signaling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Acetogenin isolated from AM effectively inhibited the survival of PA-1 ovarian cancer cells through impaired EGF signaling.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929866527666200916141730","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T04:42:40Z","timestamp":1600317760000},"page":"304-314","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Acetogenin Extracted from Annona muricata Prevented the Actions of EGF in PA-1 Ovarian Cancer Cells"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-4317","authenticated-orcid":true,"given":"Loganayaki","family":"Periyasamy","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu 641 021, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3235-5837","authenticated-orcid":true,"given":"Bharathi","family":"Muruganantham","sequence":"additional","affiliation":[{"name":"Karpagam Cancer Research Centre, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu 641 021, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9991-0201","authenticated-orcid":true,"given":"Malarvizhi","family":"Deivasigamani","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu 641 021, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7973-8347","authenticated-orcid":true,"given":"Hariprasath","family":"Lakshmanan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu 641 021, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-9081","authenticated-orcid":true,"given":"Sridhar","family":"Muthusami","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu 641 021, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1021\/np960037q","volume":"59","author":"Rieser M.J.","year":"1996","unstructured":"Rieser M.J.; Gu Z.M.; Fang X.P.; Zeng L.; Wood K.V.; McLaughlin J.L.; Five novel mono-tetrahydrofuran ring acetogenins from the seeds of Annona muricata. J Nat Prod 1996,59(2),100-108","journal-title":"J Nat Prod"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1021\/np0105578","volume":"65","author":"Liaw C.C.","year":"2002","unstructured":"Liaw C.C.; Chang F.R.; Lin C.Y.; Chou C.J.; Chiu H.F.; Wu M.J.; Wu Y.C.; New cytotoxic monotetrahydrofuran annonaceous acetogenins from Annona muricata. J Nat Prod 2002,65(4),470-475","journal-title":"J Nat Prod"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1055\/s-2003-38485","volume":"69","author":"Chang F.R.","year":"2003","unstructured":"Chang F.R.; Liaw C.C.; Lin C.Y.; Chou C.J.; Chiu H.F.; Wu Y.C.; New adjacent Bis-tetrahydrofuran Annonaceous acetogenins from Annona muricata. Planta Med 2003,69(3),241-246","journal-title":"Planta Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.bbrc.2004.06.160","volume":"321","author":"Abuharbeid S.","year":"2004","unstructured":"Abuharbeid S.; Apel J.; Sander M.; Fiedler B.; Langer M.; Zuzarte M.L.; Czubayko F.; Aigner A.; Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun 2004,321(2),403-412","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/01635581.2011.563027","volume":"63","author":"Dai Y.","year":"2011","unstructured":"Dai Y.; Hogan S.; Schmelz E.M.; Ju Y.H.; Canning C.; Zhou K.; Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression. Nutr Cancer 2011,63(5),795-801","journal-title":"Nutr Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2012.03.031","volume":"323","author":"Torres M.P.","year":"2012","unstructured":"Torres M.P.; Rachagani S.; Purohit V.; Pandey P.; Joshi S.; Moore E.D.; Johansson S.L.; Singh P.K.; Ganti A.K.; Batra S.K.; Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Lett 2012,323(1),29-40","journal-title":"Cancer Lett"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/jcp.24258","volume":"228","author":"Do M.T.","year":"2013","unstructured":"Do M.T.; Hwang Y.P.; Kim H.G.; Na M.; Jeong H.G.; Mollugin inhibits proliferation and induces apoptosis by suppressing fatty acid synthase in HER2-overexpressing cancer cells. J Cell Physiol 2013,228(5),1087-1097","journal-title":"J Cell Physiol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jep.2014.08.011","volume":"156","author":"Zorofchian Moghadamtousi S","year":"2014","unstructured":"Zorofchian Moghadamtousi S; Karimian H; Rouhollahi E; Paydar M; Fadaeinasab M; Annona muricata leaves induce G cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells J Ethnopharmacol 2014,156,277-89","journal-title":"J Ethnopharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3892\/ijo.2015.2931","volume":"46","author":"Wang Y.","year":"2015","unstructured":"Wang Y.; Han A.; Chen E.; Singh R.K.; Chichester C.O.; Moore R.G.; Singh A.P.; Vorsa N.; The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. Int J Oncol 2015,46(5),1924-1934","journal-title":"Int J Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.2174\/1381612822666160531163144","volume":"22","author":"Prabhakaran K.","year":"2016","unstructured":"Prabhakaran K.; Ramasamy G.; Doraisamy U.; Mannu J.; K R.; Murugesan J.R.; Polyketide natural products, acetogenins from graviola (Annona muricata L), its biochemical, cytotoxic activity and various analyses through computational and bio-programming methods. Curr Pharm Des 2016,22(34),5204-5210","journal-title":"Curr Pharm Des"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1525-1438.1995.05010049.x","volume":"5","author":"Kaufmann M.","year":"1995","unstructured":"Kaufmann M.; Von Minckwitz G.; K\u00fchn W.; Schmid H.; Costa S.; Goerttler K.; Bastert G.; Combination of new biologic parameters as a prognostic index in epithelial ovarian carcinoma. Int J Gynecol Cancer 1995,5(1),49-55","journal-title":"Int J Gynecol Cancer"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/mc.20504","volume":"48","author":"Xia W.","year":"2009","unstructured":"Xia W.; Wei Y.; Du Y.; Liu J.; Chang B.; Yu Y.L.; Huo L.F.; Miller S.; Hung M.C.; Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 2009,48(7),610-617","journal-title":"Mol Carcinog"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/jcp.22486","volume":"226","author":"Cinghu S.","year":"2011","unstructured":"Cinghu S.; Anandharaj A.; Lee H.C.; Yu J.R.; Park W.Y.; FTS (fused toes homolog) a novel oncoprotein involved in uterine cervical carcinogenesis and a potential diagnostic marker for cervical cancer. J Cell Physiol 2011,226(6),1564-1572","journal-title":"J Cell Physiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00432-014-1802-4","volume":"141","author":"Muthusami S.","year":"2015","unstructured":"Muthusami S.; Prabakaran D.S.; Yu J.R.; Park W.Y.; FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in cervical cancer cells. J Cancer Res Clin Oncol 2015,141(2),203-210","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"12427","DOI":"10.1007\/s13277-014-2560-2","volume":"35","author":"Wei L.Q.","year":"2014","unstructured":"Wei L.Q.; Liang H.T.; Qin D.C.; Jin H.F.; Zhao Y.; She M.C.; MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF. Tumour Biol 2014,35(12),12427-12434","journal-title":"Tumour Biol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.21873\/anticanres.12735","volume":"38","author":"Izuchi D.","year":"2018","unstructured":"Izuchi D.; Fukagawa S.; Yotsumoto F.; Shigekawa K.; Yoshikawa K.; Hirakawa T.; Kiyoshima C.; Ouk N.S.; Urushiyama D.; Katsuda T.; Miyata K.; Ito T.; Kurakazu M.; Araki R.; Sanui A.; Miyahara D.; Murata M.; Ito H.; Shirota K.; Kuroki M.; Yasunaga S.; Miyamoto S.; Association of Serum HB-EGF value and response to chemotherapy in patients with recurrent ovarian cancer. Anticancer Res 2018,38(7),4347-4351","journal-title":"Anticancer Res"},{"key":"ref=17","first-page":"3955","volume":"37","author":"Miyata K.","year":"2017","unstructured":"Miyata K.; Yotsumoto F.; Fukagawa S.; Kiyoshima C.; Ouk N.S.; Urushiyama D.; Ito T.; Katsuda T.; Kurakazu M.; Araki R.; Sanui A.; Miyahara D.; Murata M.; Shirota K.; Yagi H.; Takono T.; Kato K.; Yaegashi N.; Akazawa K.; Kuroki M.; Yasunaga S.; Miyamoto S.; Serum Heparin-binding Epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer. Anticancer Res 2017,37(7),3955-3960","journal-title":"Anticancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4149\/neo_2018_180724N524","volume":"66","author":"Cong J.","year":"2019","unstructured":"Cong J.; Liu R.; Hou J.; Wang X.; Jiang H.; Wang J.; Effects of trastuzumab on the proliferation and apoptosis of ovarian cancer cells. Neoplasma 2019,66(2),240-244","journal-title":"Neoplasma"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1021\/ja00051a040","volume":"114","author":"Rappe A.K.","year":"1992","unstructured":"Rappe A.K.; Casewit C.J.; Colwell K.S.; Goddard W.A.; Skiff W.M.; UFF, a full periodictable force field for molecular mechanics and molecular dynamics simulations. J Am Chem Soc 1992,114,10024-10035","journal-title":"J Am Chem Soc"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461","journal-title":"J Comput Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume":"1263","author":"Dallakyan S.","year":"2015","unstructured":"Dallakyan S.; Olson A.J.; Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015,1263,243-250","journal-title":"Methods Mol Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"Laskowski R.A.","year":"2011","unstructured":"Laskowski R.A.; Swindells M.B.; LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011,51(10),2778-2786","journal-title":"J Chem Inf Model"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"Lipinski C.A.","year":"2001","unstructured":"Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J.; Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001,46(1-3),3-26","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1021\/ci300367a","volume":"52","author":"Cheng F.","year":"2012","unstructured":"Cheng F.; Li W.; Zhou Y.; Shen J.; Wu Z.; Liu G.; Lee P.W.; Tang Y.; admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 2012,52(11),3099-3105","journal-title":"J Chem Inf Model"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"Kanehisa M.","year":"2017","unstructured":"Kanehisa M.; Furumichi M.; Tanabe M.; Sato Y.; Morishima K.; KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017,45(D1),D353-D361","journal-title":"Nucleic Acids Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00418-012-0956-x","volume":"138","author":"Ogawa M.","year":"2012","unstructured":"Ogawa M.; Kojima T.; Someya M.; Nomura K.; Takasawa A.; Murata M.; Tanaka S.; Saito T.; Sawada N.; Epidermal growth factor modulates claudins and tight junctional functions in ovarian cancer cell lines. Histochem Cell Biol 2012,138(2),323-338","journal-title":"Histochem Cell Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3389\/fphar.2019.00783","volume":"10","author":"Jacobo-Herrera N.","year":"2019","unstructured":"Jacobo-Herrera N.; P\u00e9rez-Plasencia C.; Castro-Torres V.A.; Mart\u00ednez-V\u00e1zquez M.; Gonz\u00e1lez-Esquinca A.R.; Zentella-Dehesa A.; Selective acetogenins and their potential as anticancer agents. Front Pharmacol 2019,10,783","journal-title":"Front Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1021\/np960447e","volume":"59","author":"Zeng L.","year":"1996","unstructured":"Zeng L.; Wu F.E.; Oberlies N.H.; McLaughlin J.L.; Sastrodihadjo S.; Five new monotetrahydrofuran ring acetogenins from the leaves of Annona muricata. J Nat Prod 1996,59(11),1035-1042","journal-title":"J Nat Prod"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.bmcl.2014.12.088","volume":"25","author":"Yuan F.","year":"2015","unstructured":"Yuan F.; Bai G.; Chen Y.; Miao Y.; Chen J.; Li X.; Structure-activity relationships of diverse ACGs against multidrug resistant human lung cancer cell line A549\/Taxol. Bioorg Med Chem Lett 2015,25(4),787-790","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2174\/1871520615666150629101827","volume":"16","author":"Mangal M.","year":"2015","unstructured":"Mangal M.; Khan M.I.; Agarwal S.M.; Acetogenins as potential anticancer agents. Anticancer Agents Med Chem 2015,16(2),138-159","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.18632\/aging.102608","volume":"12","author":"Liu G.","year":"2020","unstructured":"Liu G.; Ruan G.; Huang M.; Chen L.; Sun P.; Genome-wide DNA copy number profiling and bioinformatics analysis of ovarian cancer reveals key genes and pathways associated with distinct invasive\/migratory capabilities. Aging (Albany NY) 2020,12(1),178-192","journal-title":"Aging (Albany NY)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"113729","DOI":"10.1016\/j.bcp.2019.113729","volume":"172","author":"Marquard F.E.","year":"2020","unstructured":"Marquard F.E.; J\u00fccker M.; PI3K\/AKT\/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol 2020,172,113729","journal-title":"Biochem Pharmacol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"Wee P.","year":"2017","unstructured":"Wee P.; Wang Z.; Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 2017,9(5),52","journal-title":"Cancers (Basel)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-17-0081","volume":"16","author":"Zanini E.","year":"2017","unstructured":"Zanini E.; Louis L.S.; Antony J.; Karali E.; Okon I.S.; McKie A.B.; Vaughan S.; El-Bahrawy M.; Stebbing J.; Recchi C.; Gabra H.; The Tumor-suppressor protein OPCML potentiates Anti-EGFR- and Anti-HER2-targeted therapy in HER2-positive ovarian and breast cancer. Mol Cancer Ther 2017,16(10),2246-2256","journal-title":"Mol Cancer Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1517\/17460441.2012.714363","volume":"7","author":"Arnott J.A.","year":"2012","unstructured":"Arnott J.A.; Planey S.L.; The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov 2012,7(10),863-875","journal-title":"Expert Opin Drug Discov"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejps.2019.04.020","volume":"134","author":"Lee Y.","year":"2019","unstructured":"Lee Y.; Choi S.Q.; Quantitative analysis for lipophilic drug transport through a model lipid membrane with membrane retention. Eur J Pharm Sci 2019,134(15),176-184","journal-title":"Eur J Pharm Sci"},{"key":"ref=37","author":"Bennion B.J.","year":"2017","unstructured":"Bennion B.J.; Be N.A.; McNerney M.W.; Lao V.; Carlson E.M..; Valdez C.A.; Malfatti M.A.; Enright H.A.; Nguyen T.H.; Lightstone F.C.; Carpenter T.S.; Predicting a drug's membrane permeability: a computational model validated with in vitro permeability assay data J phy chem 2017","journal-title":"J phy chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1021\/acs.jmedchem.7b00237","volume":"60","author":"Matsson P.","year":"2017","unstructured":"Matsson P.; Kihlberg J.; How Big Is Too Big for Cell Permeability? J Med Chem 2017,60(5),1662-1664","journal-title":"J Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.drudis.2016.02.005","volume":"21","author":"Whitty A.","year":"2016","unstructured":"Whitty A.; Zhong M.; Viarengo L.; Beglov D.; Hall D.R.; Vajda S.; Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. Drug Discov Today 2016,21(5),712-717","journal-title":"Drug Discov Today"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/ci800293n","volume":"49","author":"Hevener K.E.","year":"2009","unstructured":"Hevener K.E.; Zhao W.; Ball D.M.; Babaoglu K.; Qi J.; White S.W.; Lee R.E.; Validation of molecular docking programs for virtual screening against dihydropteroate synthase. J Chem Inf Model 2009,49(2),444-460","journal-title":"J Chem Inf Model"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/molecules21111575","volume":"21","author":"Garc\u00eda-Godoy M.J.","year":"2016","unstructured":"Garc\u00eda-Godoy M.J.; L\u00f3pez-Camacho E.; Garc\u00eda-Nieto J.; Nebro A.J.; Aldana-Montes J.F.; Molecular docking optimization in the context of multi-drug resistant and sensitive EGFR mutants. Molecules 2016,21(11),1575","journal-title":"Molecules"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e0217031","DOI":"10.1371\/journal.pone.0217031","volume":"14","author":"Tavakoli F.","year":"2019","unstructured":"Tavakoli F.; Ganjalikhany M.R.; Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase. PLoS One 2019,14(5),e0217031","journal-title":"PLoS One"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"e0189147","DOI":"10.1371\/journal.pone.0189147","volume":"12","author":"Hasenahuer M.A.","year":"2017","unstructured":"Hasenahuer M.A.; Barletta G.P.; Fernandez-Alberti S.; Parisi G.; Fornasari M.S.; Pockets as structural descriptors of EGFR kinase conformations. PLoS One 2017,12(12),e0189147","journal-title":"PLoS One"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nsmb.3074","volume":"22","author":"Park E.","year":"2015","unstructured":"Park E.; Kim N.; Ficarro S.B.; Zhang Y.; Lee B.I.; Cho A.; Kim K.; Park A.K.J.; Park W.Y.; Murray B.; Meyerson M.; Beroukhim R.; Marto J.A.; Cho J.; Eck M.J.; Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol 2015,22(9),703-711","journal-title":"Nat Struct Mol Biol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/156802610790232233","volume":"10","author":"Sarkar A.","year":"2010","unstructured":"Sarkar A.; Kellogg G.E.; Hydrophobicity--shake flasks, protein folding and drug discovery. Curr Top Med Chem 2010,10(1),67-83","journal-title":"Curr Top Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e12029","DOI":"10.1371\/journal.pone.0012029","volume":"5","author":"Patil R.","year":"2010","unstructured":"Patil R.; Das S.; Stanley A.; Yadav L.; Sudhakar A.; Varma A.K.; Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS One 2010,5(8),e12029","journal-title":"PLoS One"},{"key":"ref=47","author":"Chakroborty D","year":"2019","unstructured":"Chakroborty D; Kurppa KJ; Paatero I; Ojala VK; Koivu M; Tamirat MZ; Koivunen JP; J\u00e4nne PA; Johnson MS; Elo LL; Elenius K; An unbiased in vitro screen for activating epidermal growth factor receptor mutations J Biol Chem [Epub ahead of Print]2019","journal-title":"J Biol Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"Ramalingam S.S.","year":"2020","unstructured":"Ramalingam S.S.; Vansteenkiste J.; Planchard D.; Cho B.C.; Gray J.E.; Ohe Y.; Zhou C.; Reungwetwattana T.; Cheng Y.; Chewaskulyong B.; Shah R.; Cobo M.; Lee K.H.; Cheema P.; Tiseo M.; John T.; Lin M.C.; Imamura F.; Kurata T.; Todd A.; Hodge R.; Saggese M.; Rukazenkov Y.; Soria J.C.; Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med FLAURA Investigators2020,382(1),41-50","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12859-018-2093-6","volume":"19","author":"Zou B.","year":"2018","unstructured":"Zou B.; Lee V.H.F.; Yan H.; Prediction of sensitivity to gefitinib\/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis. BMC Bioinformatics 2018,19(1),88","journal-title":"BMC Bioinformatics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2019.11.006","volume":"125","author":"Leighl N.B.","year":"2020","unstructured":"Leighl N.B.; Karaseva N.; Nakagawa K.; Cho B.C.; Gray J.E.; Hovey T.; Walding A.; Ryd\u00e9n A.; Novello S.; Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur J Cancer 2020,125,49-57","journal-title":"Eur J Cancer"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jtho.2019.09.008","volume":"15","author":"Yang J.C.","year":"2020","unstructured":"Yang J.C.; Cheng Y.; Murakami H.; Yang P.C.; He J.; Nakagawa K.; Kang J.H.; Kim J.H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M.; A Randomized phase 2 study of gefitinib with or without pemetrexed as first-line treatment in nonsquamous NSCLC with EGFR mutation: final overall survival and biomarker analysis. J Thorac Oncol 2020,15(1),91-100","journal-title":"J Thorac Oncol"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185949\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T23:08:16Z","timestamp":1723590496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185949\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929866527666200916141730","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}